



OPEN ACCESS

EDITED AND REVIEWED BY
Zhiqin Bu,
Zhengzhou University, China

*CORRESPONDENCE
Vittorio Unfer
✉ vunfer@gmail.com

RECEIVED 31 January 2025
ACCEPTED 14 February 2025
PUBLISHED 26 February 2025

CITATION
Quaresima P, Myers SH, Pintaudi B,
D'Anna R, Morelli M and Unfer V (2025)
Corrigendum: Gestational diabetes mellitus
and polycystic ovary syndrome, a position
statement from EGOI-PCOS.
Front. Endocrinol. 16:1569086.
doi: 10.3389/fendo.2025.1569086

COPYRIGHT
© 2025 Quaresima, Myers, Pintaudi, D'Anna,
Morelli and Unfer. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Gestational diabetes mellitus and polycystic ovary syndrome, a position statement from EGOI-PCOS

Paola Quaresima¹, Samuel H. Myers², Basilio Pintaudi^{3,4},
Rosario D'Anna^{3,5}, Michele Morelli⁶ and Vittorio Unfer^{3,7*}

¹Department of Obstetrics and Gynecology, Azienda Sanitaria Provinciale di Cosenza, Cosenza, Italy, ²R&D Department, Lo.Li Pharma s.r.l, Rome, Italy, ³The Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), Rome, Italy, ⁴Azienda Socio Sanitaria Territoriale (ASST) Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁵Department of Human Pathology, University of Messina, Messina, Italy, ⁶Department of Obstetrics and Gynecology, Annunziata Hospital, Cosenza, Italy, ⁷UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy

KEYWORDS

gestational diabetes mellitus, polycystic ovary syndrome, insulin, metformin, myo-inositol

A Corrigendum on

Gestational diabetes mellitus and polycystic ovary syndrome, a position statement from EGOI-PCOS

By Quaresima P, Myers SH, Pintaudi B, D'Anna R, Morelli M and Unfer V (2025) *Front. Endocrinol.* 16:1501110. doi: 10.3389/fendo.2025.1501110

In the published article, there was an error in **Table 1** as published. The fasting glucose for IADPSG cut off was written as 95, this was a typo, as it should be 92. The correct table appears below.

In the published article, there was a typo in the text.

A correction has been made to *Section 6.4*, Paragraph 1. This sentence previously stated:

“In nature the two most common stereoisomers of inositol are myo-inositol (MI) and D-chiro-inositol, these molecules function as second messengers of various endocrine signals including follicle stimulating hormone (FSH), thyroid stimulating hormone (LH) and insulin (74).”

The corrected sentence appears below:

“In nature the two most common stereoisomers of inositol are myo-inositol (MI) and D-chiro-inositol, these molecules function as second messengers of various endocrine signals including follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH) and insulin (74).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Summary of diagnostic and screening criteria for GDM- adapted from Choudhury et al. (26).

| Criteria | Glucose (g) | Time (h) | Glucose threshold (mg/dl) | | | | Ref |
|---------------|-------------|----------|---------------------------|-----|-----|-----|------|
| | | | Fasting | 1h | 2 h | 3 h | |
| WHO (1999) | 75 | 2 | 126 | - | 140 | - | (25) |
| ADA (2004) | 100 | 3 | 95 | 180 | 155 | 140 | (28) |
| IADPSG (2010) | 75 | 2 | 92 | 180 | 153 | - | (26) |
| WHO (2013) | 75 | 2 | 95 | 180 | 153 | - | (27) |
| NICE (2015) | 75 | 2 | 101 | - | 140 | - | (30) |